HC Wainwright Raises Price Target for This Biopharmaceutical Company

Aclaris Therapeutics Inc (ACRS): A Potential Market Gamechanger with a $9 Price Target.

Disclosure: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

Aclaris Therapeutics Inc (NASDAQ: ACRS), a biopharmaceutical company focusing on dermatological and immunological diseases, has recently been the subject of an intriguing analysis by HC Wainwright. The firm se…